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(57) ABSTRACT 
The invention relates to compositions comprising a myce 
lium extract from at least one higher Basidiomycetes 
medicinal mushroom selected from the group consisting of 
Ganoa'erma adspersum, Hypsizygus ulmarium, Kuehnero 
myces mutabilis, Omphalotus olearius, Panus conchatus, 
Piptoporus betulinus, Pleurotus eryngii, and Trametes 
zonata, said composition having selective antiproliferative 
activity on the human chronic myelogenous leukemia K562 
cells and on the human prostate cancer LNCaP cells. The 
compositions are useful for treatment of chronic myelog 
enous leukemia (CML), Ph+ acute lymphoblastic leukemia 
(ALL), prostate cancer and [3-globin disorders such as sickle 
cell anemia and [3-thalassemia. 
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MUSHROOM EXTRACTS HAVING ANTICANCER 
ACTIVITY 
FIELD OF THE INVENTION 
[0001] The present invention relates to extracts of medici 
nal mushrooms, to compositions comprising them and to 
methods for treatment of chronic myelogenous leukemia, 
Ph+ acute lymphoblastic leukemia, prostate cancer and 
[3-globin disorders by administration of said extract or 
composition. 
Abbreviations 
[0002] ABL: Abelson leukemia virus; ALL: acute lym 
phoblastic leukemia; AR: androgen receptor; BCR: break 
point cluster region; CML: chronic myelogenous leukemia; 
ALL: acute lymphoblastic leukemia; CV: coef?cient of 
variance; DMSO: dimethyl sulfoxide; ELISA: enZyme 
linked immunoabsorbent assay; ERK: extracellular signal 
regulated kinase; HBM: higher Basidiomycetes mushrooms; 
HDP: host defense potentiators; HMW: high molecular 
Weight; HSP: heat shock protein; IC50: inhibitory concen 
tration; JNK: c-Jun N-terminal kinase; LMW: loW molecular 
Weight; MAPK: mitogen-activated protein kinase; PARP: 
poly(ADP-ribose) polymerase; PBS: phosphate-buffered 
saline; Ph: Philadelphia cromosome; Ph+: Ph positive; PSA: 
prostate-speci?c antigen. 
BACKGROUND OF THE INVENTION 
[0003] Higher Basidiomycetes mushrooms (HBM) repre 
sent a major and still largely untapped source of potent neW 
pharmaceutical products. Of approximately 15,000 knoWn 
species, 2,000 are safe for human consumption, and about 
650 of them possess medicinal properties (Wasser et al., 
2000; HaWksWorth, 2001; Kirk et al., 2001; Wasser, 2002). 
Of about 650 mushroom species With knoWn medicinal 
properties, only about 20 species are in use at the present 
(Chang, 2001). Most traditional knoWledge about medicinal 
properties of HBM comes from the Far East (China, Japan, 
Korea, Russian Siberia). Many pharmaceutical substances 
With potent and unique properties have recently been 
extracted from mushrooms and have made their Way all 
around the World. Unique anticancer medicines Were pre 
pared from these extracts such as polysaccharides lentinan, 
krestin, and schiZophyllan (MiZuno, 1999). 
[0004] Present studies suggest that HBM are probiotic, 
i.e., they help the body to strengthen itself and ?ght off 
illness by maintaining physiological homeostasis, restoring 
the body’s balance and natural resistance to disease. The 
compounds they contain have been classi?ed as Host 
Defense Potentiators (HDP), Which can have immune sys 
tem enhancement properties. That is one of the reasons Why 
they are currently used as adjuncts to cancer treatments in 
many countries (Tomatis et al., 2001). In Japan, Russia, 
China, and the USA, several polysaccharide anticancer and 
immunomodulating agents have been developed from the 
fruiting body, mycelia, and culture medium of various 
medicinal mushrooms (Lentinus edoa'es, Ganoa'erma luci 
dum, Schizophyllum commune, Trametes versicolor; Inono 
[us obliquus, Hypsizygus marmoreus, and Flammulina 
velutipes) (IkekaWa, 2001). 
[0005] Mushroom HDP include hemicellulose (AHCC), 
polysaccharides, polysaccharide-peptides, nucleosides, trit 
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erpenoids, complex starches, and other metabolites. It is 
believed that combinations of these products target the 
human immune system, and also aid neuron transmission, 
metabolism, hormonal balance, and the transport of nutrients 
and oxygen. Through a host-mediated (T cell) immune 
mechanism, they help the body regulate the development of 
lymphoid stem cells and other important defense responses 
(MiZuno, 1999). 
[0006] Chronic myelogenous leukemia (CML) is a mem 
ber of a group of diseases classi?ed as myeloproliferative 
disorders, Which account for 20% of all leukemias. CML is 
a clonal disorder that is usually easily recogniZed because 
the leukemia cells of more than 95% of patients suffering 
from CML have a distinctive cytogenetic abnormality, the 
Philadelphia chromosome (Ph), that results from a recipro 
cal translocation betWeen the long arms of chromosomes 9 
and 22. This translocation results in the transfer of the 
Abelson (Abl) oncogene on chromosome 9 to an area of 
chromosome 22 that includes the breakpoint cluster region 
(Bcr) gene. This results in the presentation of a leukemia 
speci?c fusion gene (Bcr-Abl) Which gives rise to an abnor 
mal tyrosine kinase protein, p210 (Bcr-Abl), With increased 
activity (Clarkson et al., 1997; CorteZ et al., 1997). In 
addition, the Ph chromosome is also found in a siZeable 
portion of acute lymphoblastic leukemia (ALL) patients 
(25-30%) and in a small number of acute myeloid leukemia 
(AML) cases (Drexler et al., 1999). Bcr-Abl expressing 
leukemic blasts are highly resistant to different classes of 
chemotherapeutic drugs. K562 cells, derived from patients 
With CML in blast crisis (LoZZio and LoZZio, 1975), Which 
express p210B°"Ab1, have been shoWn to be highly resistant 
to apoptosis induced by many chemotherapeutic agents 
(McGahon et al., 1994). Overexpression of Bcr-Abl has 
been implicated in inhibiting apoptosis induced by cytokine 
deprivation, DNA damage, and a variety of chemotherapeu 
tic drugs (CorteZ et al., 1997). Thus, the Bcr-Abl fusion 
protein has been suggested to function as an antiapoptotic 
factor, and overexpression of the Bcr-Abl protein in K562 
cells may, in part, account for the resistance of these cells to 
apoptosis, thereby leading to the accumulation of leukemic 
blasts in patients With chronic myeloid leukemia (Urbano et 
al., 1998). 
[0007] Gleevec (imatinib mesylate, also knoWn as STI 
571), is being used as oral treatment for patients With CML. 
It is a protein-tyrosine kinase inhibitor that inhibits the 
Bcr-Abl tyrosine kinase. 
[0008] Apoptosis, programmed cell death, is a genetically 
controlled ablation of cells during development. It is char 
acteriZed by chromatin condensation, nuclear fragmentation, 
cell membrane blebbing, apoptotic body formation, and 
mitochondrial changes, including enhanced membrane per 
meability, fall of mitochondrial membrane potential (A‘Pm), 
and release of cytochrome c into the cytosol. Induction of 
apoptosis is the principal mechanism by Which the majority 
of chemotherapeutic agents exert their function. Conse 
quently, failure to undergo apoptosis is the likely mechanism 
mediating drug resistance in tumors. 
[0009] Antitumor and anticancer properties have been 
studied in mushrooms. The three mushrooms Which have the 
broadest range of action are Shiitake (Lentinus edodes), 
Reishi (Ganoa'erma lucidum) and Maitake (Grifola fron 
dosa). Another popular mushroom is Coriolus versicolor, 
also knoWn as Trametes versicolor. 
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[0010] Among the main active substances found in 
medicinal mushrooms are: 
[0011] lentinan, a highly puri?ed polysaccharide 
fraction extracted from Shiitake mushrooms, is an 
approved drug in Japan. It is generally administered by 
injection and has been used as an agent to prolong 
survival of patients in conventional cancer therapy, for 
example, in boWel cancer, liver cancer, stomach cancer, 
ovarian cancer and lung cancer; it also stimulates the 
production of T-lymphocytes and natural killer cells 
and can potentiate the effect of AZT in the antiviral 
treatment of AIDS; 
[0012] (ii) a substance knoWn as activated hexose 
containing compound (AHCC) or 1,3-beta glucan is an 
active fraction found in shiitake mushrooms Which has 
shoWn anti-cancer properties in some human, animal 
and lab studies in Japan; 
[0013] (iii) polysaccharide-peptide or PSP, a proteogly 
can from T rametes versicolor, also knoWn as Coriolus 
versicolor, has been Widely used in China as anticancer 
and immunomodulatory agent in the treatment of 
patients With cancer of the stomach, esophagus, lung, 
ovary and cervix; 
[0014] (iv) the immunostimulating polysaccharide kres 
tin, polysaccharide-K or PSK is a popular Japanese 
extract made from T rametes versicolor. PSK has been 
shoWn in several studies to help cancer patients under 
going chemotherapy, and signi?cantly extended sur 
vival at ?ve years or beyond in cancers of the breast, 
liver, prostate, stomach, colon-rectum, esophagus, 
nasopharynx, and lung (non-small cell types). PSK acts 
directly against tumor cells as Well as indirectly in the 
host to boost cellular immunity by increasing White cell 
activity and increasing natural killer cell function. The 
list of cancers for Which it is knoWn to be useful in 
animals includes adenosarcoma, ?brosarcoma, masto 
cytoma, plasmacytoma, melanoma, sarcoma, carci 
noma, mammary cancer, colon cancer, and lung cancer; 
and 
[0015] (v) a dietary supplement prepared from extracts 
of Trametes versicolor is in use for general health 
purposes. Ethanol extracts (70%) of Trametes versi 
c0l0r dietary supplement reduced LNCaP cell groWth 
and doWn-regulated the levels of secreted prostate 
speci?c antigen (PSA), raising the possibility of 
chemopreventive potential for hormone-refractory 
prostate cancer (Hsieh and Wu, 2001). 
[0016] We have not found in the literature any publication 
disclosing the activity of mushroom extracts on CML cells. 
[0017] Although most bioactive substances isolated from 
mushrooms are high-molecular-Weight (HMW) polysaccha 
rides, our interest is in loW-molecular-Weight (LMW) com 
pounds capable of exhibiting antitumor activity. We have 
thus focused on the search for novel compounds that induce 
apoptosis in CML cells and might be useful in the therapy 
of patients With CML. 
SUMMARY OF THE INVENTION 
[0018] It has noW been found, in accordance With the 
present invention, that mycelium extracts of some higher 
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Basidiomycetes mushrooms selectively inhibit the groWth, 
promote apoptosis, and induce erythroid differentiation of 
K562 cells, a human CML cell line, and also inhibit the 
groWth of LNCaP cells, a human hormone-responsive pros 
tate cancer cell line. 
[0019] The present invention thus relates, in one aspect, to 
a composition comprising a mycelium extract from at least 
one higher Basidiomycetes medicinal mushroom selected 
from the group consisting of Ganoa'erma adspersum, Hyp 
sizygus ulmarium, Kuehneromyces mutabilis, Omphalotus 
olearius, Panus conchatus, Piptoporus betulinus, Pleurotus 
eryngii, and T rametes zonata, said composition having 
selective antiproliferative activity, or selective apoptosis 
inducing activity on the human chronic myelogenous leu 
kemia K562 cells and on the human prostate cancer LNCaP 
cells. 
[0020] The compositions may be in the form of pharma 
ceutical compositions or they may be comprised Within a 
food or beverage. 
[0021] Further provided are methods for the treatment of 
a patient suffering from CML, ALL, prostate cancer or a 
[3-globin disorder consisting of sickle cell anemia and 
[3-thalassemia, Which comprises administration of a compo 
sition of the invention to said patient in need. 
BRIEF DESCRIPTION OF THE FIGURES 
[0022] FIG. 1 shoWs the effect of mycelium crude extracts 
on the viability of K562 cells. K562 cells Were plated in 
6-Well plates at 1><105 cells/ml (Day —1). TWenty-four hours 
later (Day 0), 500 pig/ml of mycelium crude extracts Methl 
14, MH428, MC293; MH161, Meth178, MH210, M117, and 
Meth134 (see Tables 1 and 3 for mushroom species) Were 
added and cell numbers Were monitored for 4 days by trypan 
blue exclusion assay as described in Materials and Methods. 
Experiments Were carried out in duplicate. Changes in 
duplicate samples Were minimal With % CV beloW 10% in 
all experiments. This experiment Was repeated tWice With 
similar outcomes. 
[0023] FIGS. 2A-2B depict Western blots shoWing cleav 
age of PARP by mushroom extracts. K562 cells Were plated 
in T25 ?asks at 1><105 cells/ml. TWenty-four hours later 
mycelium crude extracts MC293, MH428, tyrphostin 
AG957 (2A), MH210, Meth178, MH17, and Meth134 (2B) 
Were added at 500 pig/ml and 250 pig/ml for 48 hours. Cell 
lysates Were resolved into 8% SDS-polyacrylamide gel 
electrophoresis SDS-PAGE) folloWed by transfer to nitro 
cellulose ?lters. Western Blotting Was performed as 
described in Materials and Methods in Which monoclonal 
anti-PARP antibody Was used (Santa CruZ, USA). 
[0024] FIGS. 3A-3B depict Western blots shoWing the 
effect of mushroom extracts on the expression of p2l0Bc"Abl 
in K562 cells. K562 cells Were plated in T25 ?asks at 1><105 
cells/ml. TWenty-four hours later, tyrphostin AG957, mush 
room extracts MH210, Meth178, MH17 (3A), tyrphostin 
AG957, Meth134, MC293, and MH428 (3B) Were added at 
500 pig/ml and 250 pig/ml for 48 hr. Western Blotting Was 
performed as described in Materials and Methods, in Which 
monoclonal c-Abl antibody Was used (Santa CruZ, USA). 
Filters Were stripped and re-probed With loading control, 
monoclonal [3-actin antibody (Santa CruZ, USA). 
[0025] FIG. 4 depicts Western blots shoWing the effect of 
Gleevec on the phosphorylation of Wild-type Bcr-Abl and 
mutated Bcr-Abl T315I and E255K. 
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[0026] FIG. 5 depicts Western blots showing inhibition of 
Bcr-Abl phosphorylation in BaF3 cell lines by DCM540. 
[0027] FIG. 6 depicts Western blots showing inhibition of 
Bcr-Abl phosphorylation in K562 cell line by DCM540. 
DETAILED DESCRIPTION OF THE 
INVENTION 
[0028] The present invention provides novel extracts of 
higher Basidiomycetes medicinal mushrooms selected from 
the group consisting of Ganoa'erma adspersum, Hypsizygus 
ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, 
Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, 
and T rametes zonata, said extracts being obtained from dry 
mycelium of the mushrooms by solvent extraction. Preferred 
mushrooms are Omphalotus olearius, more preferably the 
strain Omphalotus olearius (DC.:Fr.)Fr., Piptoporus betuli 
nus, more preferably the strain Piptoporus betulinus 
(Bull.:Fr.) P. Karst., and Trametes zonata, more preferably 
the strain T rametes zonata (Nees.:Fr.) Pilat. 
[0029] The extraction is performed With an extraction 
solvent comprising one or more organic solvents, and 
optionally comprising Water. Examples of organic solvents 
that can be used according to the invention are, Without 
being limited to, methanol, ethanol, acetonitrile, ethyl 
acetate, chloroform, hexane, cyclohexane, isooctane and 
dichloromethane. 
[0030] In one embodiment, the extraction solvent is a sole 
organic solvent used alone, e.g. dichloromethane (DCM), 
methanol or ethanol, or together With Water, preferably 
ethanol, more preferably 70% ethanol. In another embodi 
ment, the solvent is a mixture of tWo organic solvents, 
optionally With Water, such as methanol and ethyl acetate, 
preferably 10-60% methanol and 20-40% ethyl acetate, 
more preferably, 11% methanol and 22% ethyl acetate or 
50% methanol and 33% ethyl acetate, or methanol and 
chloroform, preferably 50% methanol and 33% chloroform. 
[0031] The mushrooms are groWn initially in agar plates at 
27° C. and are then transferred to liquid media and groWn in 
a suitable medium in submerged conditions for about 2-3 
Weeks. Dry mycelium is extracted With the solvents of 
choice and tested for biological activity. 
[0032] As used herein in the speci?cation, the terms and 
phrases set out beloW have the meanings Which folloW: 
[0033] For the extraction solvents, “Eth” means 70% 
ethanol, “E” means a mixture of 33% ethyl acetate and 50% 
methanol, “H” means a mixture of 22% ethyl acetate and 
11% methanol, “C” means a mixture of 33% chloroform and 
50% methanol (the remainder in these cases is Water), and 
“DCM” means 100% dichloromethane. The letters C, E, H 
Eth, and DCM also appear in the designation of the extracts 
as de?ned beloW and in the examples. 
[0034] “MH161” means the crude mycelium extract of 
Kuehneromyces mutabilis, strain 18 in Table 1 hereinafter, in 
solvent H. 
[0035] “MH210” means the crude mycelium extract of 
Pleurotus eryngii, strain 13 in Table 1 hereinafter, in solvent 
H. 
[0036] “Meth178” means the crude mycelium extract of 
Omphalotus olearius, strain 12 in Table 1 hereinafter, in 
solvent Eth. 
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[0037] “MH17” means the crude mycelium extract of 
Piptoporus betulinus, strain 11 in Table 1 hereinafter, in 
solvent H. 
[0038] “Meth134” means the crude mycelium extract of 
Ganoa'erma adspersum, strain 8 in Table 1 hereinafter, in 
solvent Eth. 
[0039] “Meth114” means the crude mycelium extract of 
Panus conchatus, strain 7 in Table 1 hereinafter, in solvent 
Eth., 
[0040] “MC293” means the crude mycelium extract of 
Hypsizygus ulmarium, strain 4 in Table 1 hereinafter, in 
solvent C. 
[0041] “MH428” means the crude mycelium extract of 
T rametes zonata, strain 1 in Table 1 hereinafter, in solvent H. 
[0042] “Meth162” means the crude mycelium extract of 
Kuehneromyces mutabilis, strain 18 in Table 1 hereinafter, in 
solvent Eth. 
[0043] “Meth215” means the crude mycelium extract of 
Pleurotus eryngii, strain 13 in Table 1 hereinafter, in solvent 
Eth. 
[0044] “Meth194” means the crude mycelium extract of 
Pholiota Aurivella, strain 31 in Table 1 hereinafter, in 
solvent Eth. 
[0045] “Meth327” means the crude mycelium extract of 
T mmetes 201mm, strain 1 in Table 1 hereinafter, in solvent 
Eth. 
[0046] “DCM540” means the crude mycelium extract of 
T rametes zonata, strain 1 in Table 1 hereinafter, in solvent 
DCM. 
[0047] “K562 cells” means the human chronic myelog 
enous leukemia cell line. 
[0048] Once obtained, the extracts are tested for antipro 
liferative activity on the K562 cells. Extracts that inhibit the 
groWth of K562 cells, but do not inhibit the groWth of other 
tumor or normal cells, are speci?c to the K562 cells and are 
suitable candidates for treatment of CML. The extracts may 
be further tested to see Whether they promote apoptosis in 
K562 cells, in Which case they Will be more preferred 
candidates for treatment of CML patients. 
[0049] The extracts selective for K562 cells are also tested 
to see Whether they induce erythroid differentiation in K562 
cells. Extracts that induce erythroid differentiation are suit 
able candidates for treatment of a [3-globin disorder such as 
sickle cell anemia and [3-thalassemia, 
[0050] The extracts are also tested for antiproliferative 
activity on human prostate cancer LNCaP cells. Extracts that 
inhibit the groWth of LNCaP cells, but do not inhibit the 
groWth of other tumor or normal cells, are speci?c to the 
LNCaP cells and are suitable candidates for treatment of 
prostate cancer. The extracts may be further tested to see 
Whether they promote apoptosis in LNCaP cells, in Which 
case they Will be more preferred candidates for treatment of 
prostate cancer patients. 
[0051] Thus, according to the present invention, 42 spe 
cies of HBM Were cultivated as pure cultures in submerged 
conditions, and dry mycelium Were used to prepare 168 
different crude extracts. The crude extracts Were used to 
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evaluate antiproliferative activity against a number of cancer 
cell lines, including K562, Jurkat (human T lymphoblast 
cells), HT29 (human colon adenocarcinoma cells), 
MH3924A (rat Morris hepatoma), and ABAE (adult bovine 
aortic endothelial cells) using XTT proliferation assay. 
[0052] Forty-four different crude extracts Were selected 
With antiproliferative effect against K562 cells and eight 
mycelium extracts Were K562-selective compared With 
MH3924A, HT29, ABAE, and Jurkat cells. GroWth inhibi 
tion against K562 ranged from 51% to 78% compared With 
solvent-treated samples. Most crude extracts exhibited a 
complete or partial cytostatic effect against K562 cells. 
[0053] The antiproliferative effect observed by the 
selected crude extracts Was attributed to the induction of 
apoptosis pathWay as determined by Apostain ELISA assay 
and by monitoring PARP cleavage. Interestingly, crude 
extract MH428 Was the most active extract in inducing 
apoptosis of K562 cells. 
[0054] In addition, expression levels of p21 Were 
affected by the presence of the selected crude extracts. Our 
data revealed a signi?cant inhibition of p210B°I'Abl expres 
sion by MH428 extract, a moderate effect by MH17, and 
minor changes by the other extracts. 
OBcr-Abl 
[0055] Furthermore, mycelium crude extracts Were active 
in inducing erythroid differentiation in K562 cells. Crude 
extracts Meth178, MH17, and MH428 shoW signi?cant 
ability to induce hemoglobin production in K562 cells as 
indicative of erythroid differentiation. 
[0056] Data presented in accordance With the present 
invention illustrate the potential of the mycelium extracts, 
particularly the MH428 extract, in CML therapy. This 
extract Was prepared from Trametes zonata and Was also 
active against LNCaP cells, indicating that T rametes zonata 
extract is active in inhibiting hormone-refractory prostate 
cancer cells. 
[0057] The mycelium extracts obtained as described 
above are concentrated and puri?ed for human use. Con 
centration can be carried out by conventional techniques 
such as thermal, decompressing thermal, activated carbon or 
ion exchange resin methods. The concentrated extract is then 
puri?ed to yield a puri?ed extract of one or more puri?ed 
compositions using standard techniques such as column 
chromatography, fractional distillation, preparative TLC 
(thin layer chromatography), preparative HPLC (high per 
formance liquid chromatography), CPC (centrifugal parti 
tion chromatography) or other techniques knoWn to those 
skilled in the art. After concentration and puri?cation, the 
product is dried by any conventional technique such as 
air-dry, hot-blast drying, spray dry, and freeZe-dry methods. 
[0058] The invention also provides a composition com 
prising a mycelium extract of the invention. The composi 
tion may be a pharmaceutical composition, in Which case the 
extract is in admixture With one or more pharmaceutically 
acceptable carriers. The composition may also be in the form 
of food or beverage. 
[0059] For formulation of the compositions of the inven 
tion, poWders of the extract may be used in that form directly 
as a loose poWder or encapsulated poWder, or may be 
formulated into capsules, caplets, tablets and similar dosage 
forms. Further, poWders may be formulated Within liquid 
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pervious membranes such as ?lters, meshes and the like, 
such as a tea bag-type infuser, for generating liquids con 
taining the dissolved extract. The poWder form of the extract 
may also be incorporated into liquids, formulated as solu 
tions, dispersions or suspensions by dissolving the extract, 
for example as a drink, tincture, or drop. The extract may be 
administered alone, or With a carrier. 
[0060] The extract can be prepared alone or as an active 
ingredient in pharmaceutical compositions including non 
toxic, pharmaceutically acceptable carriers, diluents and 
excipients, as are Well knoWn in the art (see, for example 
Merck Index, Merck & Co., RahWay, N.J.; and Gilman et al., 
(eds) (1996) Goodman and Gilman’s: The Pharmacological 
Bases of Therapeutics, 8.sup.th Ed., Pergamon Press). For 
standard dosages of conventional pharmacological agents, 
see, e.g., Physicians Desk Reference (1997 Edition); and 
US. Pharmacopeia National Formulary (1995) United 
States Pharmacopeial Convention Inc., Rockville, Md. 
Compositions may also include ?avors, colorings, coatings, 
etc. All agents must be non-toxic and physiologically 
acceptable for the intended purpose, and must not substan 
tially interfere With the activity of the extract so as to 
deleteriously affect the desired biological activity thereof. 
Ingredients are thus only included in therapeutically accept 
able amounts 
[0061] The dosage of the extract to be administered 
depends upon many factors that are Well knoWn to those 
skilled in the art, for example, the particular form of the 
extract; the stage of the disease; the age, Weight and clinical 
condition of the patient; any concurrent therapeutic treat 
ments; and the experience and judgment of the clinician or 
practitioner administering the therapy. The extract may be 
administered orally, intraperitoneally, or intravenously at a 
dosage range and frequency (e.g., at least once daily) such 
that the level of active extract is maintained in the body. The 
dosage range varies With the route of administration, and the 
form and potency of the extract; for example, one dose of the 
extract in a capsule taken orally may contain for example 
100-2000 mg of the extract, preferably 200-1500 mg, more 
preferably 250-1000 mg, still more preferably 500-800 mg. 
The extract is preferably administered in spaced dosages 
throughout the day to maintain the level of active extract in 
the body. 
[0062] The present invention further provides food or 
beverage containing a composition of the invention. Thus, 
for example, the extract may be added to fruit juice, veg 
etable juice, all kinds of tea and nutrient drinks possibly 
containing nutraceuticals of choice such as vitamins, min 
erals, antioxidants and the like. 
[0063] The invention further provides a method of treating 
a Philadelphia chromosome-positive (Ph+) leukemia patient 
such as CML and ALL Ph+ leukemia patients, comprising 
administering to a patient in need a therapeutically effective 
amount of a composition of the invention, preferably a 
composition comprising a mycelium extract of Piptoporus 
betulinus or T rametes zonata. 
[0064] Further provided by the invention is a method of 
treating sickle cell anemia comprising administering to a 
patient in need a therapeutically effective amount of a 
composition of the invention, preferably a composition 
comprising a mycelium extract of of Omphalotus olearius, 
Piptoporus betulinus, or T rametes zonata. 
US 2006/0045887 A1 
[0065] The invention still further relates to a method of 
treating [3-thalassemia comprising administering to a patient 
in need a therapeutically effective amount of a composition 
of of the invention, preferably a composition comprising a 
mycelium extract of of Omphalotus olearius, Piptoporus 
betulinus, or Trametes zonata. 
[0066] The invention yet further provides a method of 
treating prostate cancer comprising administering to a 
patient in need a therapeutically effective amount of a 
composition of the invention, preferably a composition 
comprising a mycelium extract of T rametes zonata. 
[0067] The invention Will noW be illustrated by the fol 
loWing non-limiting Examples. 
EXAMPLES 
Materials and Methods 
(i) Mushroom Species, Cultivation and Extraction 
[0068] The strains used in the present invention are from 
a culture collection of HBM (acronym HAI) of the Institute 
of Evolution, University of Haifa, Israel (Wasser et al., 
2002), that contains presently over 1000 strains of edible and 
medicinal mushrooms. About 200 species Were collected in 
different ecological regions of Israel, and neW strains have 
been permanently introduced into the collection. The col 
lection also contains many diverse strains of Well-known 
medicinal mushrooms from North America, Europe, and 
other parts of the World. Table 1 hereinafter shoWs a list of 
mushroom species used to prepare the mycelium crude 
extracts tested herein. Mushrooms Were groWn initially in 
agar plates at 27° C., and then transferred to liquid media to 
generate a starter culture. Large-scale groWth Was carried 
out in 500 ml liquid medium in 2-liter Erlenmeyer for 2-3 
Weeks at 27° C. With shaking at 180 rpm. 
[0069] Medicinal mushrooms Were groWn in submerged 
condition, and mycelium Was dried and used to prepare 
crude extracts using various mixtures of aqueous organic 
solvents, including Eth (70% ethanol), E (33% ethyl acetate, 
50% methanol), H (22% ethyl acetate, 11% methanol), and 
C (33% chloroform, 50% methanol). Obtained yield of 
crude extract With the various mixtures of organic solvents 
is shoWn in Table 1 in mg/gram of dried mycelium used. ND 
indicates ‘not determined’. 
(ii) Mushroom GroWth Medium 
[0070] Mushrooms Were groWn in liquid or solid media 
containing 2% glucose, 0.1% bacteriological peptone, 0.1% 
yeast extract, 0.1% KH2PO4, 0.1% MgSO4, and 1.7% of a 
Bacto-Agar in agar plates. The media Were also supple 
mented With 10 ml per 1 liter of trace solution (18 mM 
FeSO4, 3.7 mM MnSO4, 1.5 mM ZnSO4, 0.8 mM CuSO4). 
(iii) Preparation of Mycelium Crude Extracts 
[0071] Dry mycelium Was extracted With the four solvents 
Eth, C, E and H (see above) (1 gram of material used for 
each condition). 
(iv) Cell Lines and Cell Cultures 
[0072] Human K562, Jurkat, and HT-29 cell lines Were 
groWn in RPMI 1640 medium With L-glutamine supple 
mented With 10% fetal bovine serum. Bovine aortic arch 
derived endothelial cell and rat Morris hepatoma 
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MH3924A cells Were groWn in DMEM and supplemented 
With 10% fetal bovine serum. Human LNCaP prostate cells 
Were maintained in RPMI 1640 medium supplemented With 
10% fetal calf serum. Penicillin at 100 U/ml and strepto 
mycin at 100 pig/ml Were added to the culture media. All cell 
lines Were groWn at 37° C. in a humidi?ed atmosphere With 
5% CO2. Adherent cell lines Were transferred With 0.025% 
trypsin and 0.02% EDTA. 
(v) Cell Viability 
[0073] To determine cell groWth and viability, K562 cells 
(2><105 cells/ml) in triplicate Were incubated in 2 ml of RPMI 
1640-10% fetal calf serum (FCS) containing mycelium 
crude extracts or DMSO. The volume of the DMSO Was 
kept at 0.6% of the medium volume. At the indicated times, 
cell viability Was determined by the trypan blue exclusion 
assay (Freshney, 1987). At least 200 cells Were examined in 
each sample. Data Were expressed as % of inhibition relative 
to solvent-treated samples. 
(vi) Erythroid Differentiation 
[0074] Erythroid differentiation Was determined by moni 
toring levels of hemoglobin production in treated cells. 
K562 cells Were plated in 6-Well plates at 2><105 cells/ml, 
folloWed by treatment With various concentrations of myce 
lium extracts for 5 days. Cells Were Washed With phosphate 
buffered saline (PBS) and cell pellet Was re-suspended in 
100 pL lysis buffer (100 mM potassium phosphate pH 7.8, 
0.2% Triton X-100) and incubated for 10 min at room 
temperature. Intracellular hemoglobin levels Were deter 
mined by means of the plasma hemoglobin kit from Sigma 
(USA) according to the manufacturer’s instructions. Levels 
of hemoglobin Were normaliZed to protein concentration 
found in each sample. Protein concentration Was determined 
by DC Protein Assay Kit (Bio-Rad, USA) according to 
manufacturer’s instructions. Relative hemoglobin levels 
Were calculated in relation to solvent-treated sample, Which 
Was designated 1.0. 
(vii) XTT Cell Proliferation Assay 
[0075] The XTT assay for fungal viability is based on the 
MTT assay (Mosmann, 1983) used to monitor cell prolif 
eration groWing in suspension. In brief, K562 cells Were 
seeded in 96-Well plates at 1.5><104 cells/Well; 24 hours later 
cells Were treated With mycelium crude extracts at 1 mg/ml 
and 250 pig/ml for an additional 24 hours. 50 pL of XTT 
solution at 1.5 pig/ml Were added to each Well and Were 
incubated for three hours at 37° C. The optical density Was 
measured by multiWell plate spectrophotometer at 405 
nanometers. 
(viii) PARP Cleavage 
[0076] To analyZe poly(ADP-ribose) polymerase (PARP) 
cleavage (Dou et al., 1999), cells (2><105 cells/ml) Were 
treated With mycelium crude extracts or DMSO for the 
indicated time. Cells Were collected, Washed once With cold 
PBS, and lysed in buffer [10 mM Tris-HCl (pH 7.4), 100 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM 
Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 
0.1% SDS, 0.5% deoxycholate, 1 mM phenylmethylsulfonyl 
?uoride] for 30 min at 4° C. Cell lysate supernatants (40 pg 
protein/each) Were resolved on 8% SDS-PAGE, transferred 
to nitrocellulose membranes, and analyZed by immune 
blotting With an anti-PARP antibody (Santa CruZ Co., USA). 
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(ix) Apostain ELISA Assay 
[0077] K562 cells (1><105 cells/ml) Were treated With 
mycelium crude extracts or DMSO for 48 hours. Samples 
Were collected, Washed With PBS, resuspended in 100 pl of 
80% methanol, and kept at —20° C. for 2-3 days. BetWeen 
2500 and 5000 cells Were used for Apostain ELISA assay 
according to manufacturer’s instructions (Alexis Biochemi 
cal, USA). 
(X) Bcr-Abl Phosphorylation Assay 
[0078] K562, BaF3/Bcr-Abl Wild-type (WT), BaF3/Bcr 
Abl T3151 and BaF3/Bcr-Abl E255K cell lines Were seeded 
4 mls/Well in 6-Well plates at 5-6><105 cells/ml. Control cells 
Were treated With 2% DMSO. Gleevec-treated cells Were 
treated With 1 pM Gleevec and dichloromethane (DCM) 
extract of T zonata (# 540) at tWo concentrations: (A) at 500 
pig/ml and (B) at 1000 pig/ml, that Were added after 24 hours. 
Cells Were treated for 60 min, then collected and centrifuged 
at 5000 rpm for 5 min. Cell pellets Were lysed in lysis buffer 
(10 mM Tris, pH 7.4; 100 mM NaCl; 1 mM EDTA; 1 mM 
EGTA; 1 mM NaF; 20 mM Na4P2O7; 2 mM Na3VO4; 1% 
Triton-X100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate; 
1 mM PMSF; 10 pl protease inhibitor cocktail and phos 
phatase inhibitor cocktail Were added to every 1 ml lysate}. 
After that, 40 pg protein from each sample Were separated 
on 8% SDS-PAGE, then Western blot Was performed 
according to the manufacturer’s instructions using phospho 
c-Abl (Tyr245) Antibody (Cell Signaling Technology Co.) 
and c-Abl monoclonal antibody (Santa CruZ Biotechnol 
ogy) 
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EXAMPLE 1 
Identi?cation of Mycelium Crude Extracts that 
Inhibit Proliferation of K562 Cells 
[0079] A large number of medicinal mushrooms (42) 
shoWn in Table 1 Were cultivated in submerged conditions, 
and extracted With various extraction solvents (4), as 
described in Materials and Methods, resulting in the prepa 
ration of 168 crude mycelium extracts. The mycelium Was 
dried and used to prepare crude extracts using various 
mixtures of organic solvents including Eth (70% ethanol), E 
(33% ethyl acetate, 50% methanol), H (22% ethyl acetate, 
11% methanol), and C (33% chloroform, 50% methanol). 
The obtained yield of crude extract With the various organic 
solvents is shoWn in Table 1 in mg of crude extract/gram of 
dried mycelium. ND indicates not determined. 
[0080] Crude extracts Were screened for their ability to 
inhibit the groWth of K562, a human chronic myelogenous 
leukemia blast cell. GroWth inhibition Was evaluated by 
XTT assay as described in Materials and Methods. Cleavage 
of the tetraZolium salt XTT, sodium 3‘-[1-[(phenylamino) 
carbonyl]-3,4-tetraZolium]-bis(4-methoxy-6-nitro)benZene 
sulfonic acid hydrate, by dehydrogenase enZymes of meta 
bolically active cells yields a highly colored formaZan 
product, Which is Water soluble. This feature obviates the 
need for formaZan crystal solubiliZation prior to absorbance 
measurements, as required With the use of other tetraZolium 
salts such as MTT, and offers a simple method for evaluating 
proliferation of cells growing in suspension such as K562 
cells (Roehm et al., 1991). 
TABLE 1 
List of mushroom species tested and yield of various crude extracts 
prepared from mycelium of submerged cultures 
mg crude extract/g dry 
mycelium 
HAI strain 
No. Species, authors number C E H Eth 
1 Trametes zonata (Nees.: Fr.) Pilat 540 183 64 16 110 
2 I multicolor (Schaef?) Julich 428 100 90 70 50 
3 I hirsutus (Wulf.: Fr.) Pilat 598 376 340 462 418 
4 Hypsizygus ulmarium (Bull.: Fr.) 812 55 88 107 96 
Redhead 
5 H. decastes Sing 510 117 107 93 107 
6 H. marmoreus (Peck) Bigel. 609 144 91 82 96 
7 Panus conchatus(Bull.: Fr.) Fr. 396 100 100 100 80 
8 Ganoderma adspersum (S. Schulz.) Donk 349 245 100 230 180 
9 G. applanatus (Pers.: Wallr.) Pat. 604 210 160 200 215 
10 G. resinaceum Boud. 142 220 170 210 220 
11 Piptoporus bemlinus (Bull.: Fr.) P. Karst. 241 240 ND 200 ND 
12 Omphalotus olearius (DC.: Fr.) Fr. 173 110 100 115 140 
13 Pleurotus eryngii (DC.: Fr.) Quel. 202 156 131 169 100 
14 R ostreams (Jacq.: Fr.) Kumm. 592 200 80 70 100 
15 R salignus Kumm. 571 75 44 75 69 
16 R cystidiosus O. K. Miller 140 169 146 133 108 
17 R pulmonarius Quel. 573 169 108 75 116 
18 Kuehneromyces mutabilis (Schaef?: Fr.) 114 100 70 100 120 
Sing et A. H. Sm. 
19 Rigidopoms ulmarius (SoW.: Fr.) Imazeki 439 60 60 70 60 
20 Spongipellis litshaueri LohW 444 100 100 60 100 
21 Panellus stipticus (Bull.: Fr.) P. Karst. 520 100 90 90 70 
22 R serotinus (Pers.: Fr.) Kuhn 498 169 119 125 156 
23 Gloeophyllum odoratum (Wulf.) Imazeki 337 100 70 90 90 
24 Schizophyllum commune Fr.: Fr. 632 90 60 80 50 
25 Oudemansiella radicata (Relh.: Fr.) Sing 773 170 130 180 150 
26 O. mucida (Schrad.: Fr.) Hoehn. 181 170 100 140 130 
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List of mushroom species tested and yield of various crude extracts 
prepared from mycelium of submerged cultures 
mg crude extract/g dry 
mycelium 
HAI strain 
No. Species, authors number C E H Eth 
27 Leucoagaricus cameifolius (Gill.) S. Wasser 344 110 65 100 98 
28 L. leucothitus (Vitt.) S. Wasser 282 185 160 155 160 
29 Marasmius scorodonius Fr. 784 290 160 70 150 
30 Polypoms squamous Huds.: Fr. 242 180 75 140 80 
31 Pholiota aurivella (Batsch.: Fr.) Kumm. 236 125 80 65 88 
32 Grzfola frondosa (Dicks.: Fr.) S. F. Gray 270 173 152 193 133 
33 Fomes fomentarius (L.: Fr.) Fr. 383 163 138 63 125 
34 Lentinus edodes (Berk) Sing 313 187 193 200 207 
35 Phellinus ignarius (L.: Fr.) Quel. 785 131 113 138 103 
36 Memlius tremellosus Fr. 267 286 120 320 ND 
37 Irpex lacteus (Fr.: Fr.) Fr. 532 178 168 176 152 
38 Inonotus levis P. Karst. 796 174 144 115 118 
39 Flammulina velutipes (Curt.: Fr.) Sing 105 153 64 125 58 
40 Oxyporus obducens Donk 824 97 95 109 108 
41 Agaricus langei (Moell.) Moell. 295 88 102 46 86 
42 Funalia trogii (Berk. upud. Trog.) Bond. 352 200 130 150 60 
et Sing 
[0081] Antiproliferative activity of crude mycelium 
extracts was evaluated against K562 cells. K562 cells were 
plated in 96-well plates at 1.5><104 cells/well and 24 hours 
later were treated with mycelium crude extracts at 250 pig/ml 
and 1 mg/ml (with addition of 10 pl of stock solution to each 
well containing 100 pl of K562 cells). Twenty-four hours 
later, XTT assay was performed as described in Materials 
and Methods. 
[0082] The obtained results are summarized in Table 2. A 
total of 44 crude extracts from the 168 screened extracts 
were active in inhibiting the growth of K562 cells by more 
than 50%. The 44 crude mycelium extracts represent about 
26% of the screened extracts. The number of active extracts 
among the various extraction methods varied signi?cantly. 
With solvent mixtures H (22% ethyl acetate, 11% methanol), 
E (33% ethyl acetate, 50% methanol), C (33% chloroform, 
50% methanol), and Eth (70% ethanol), the number of K562 
active extracts were 5, 13, 12, and 14, respectively (Table 2). 
TABLE 2 
Distribution of K562 active mycelium crude extracts among the 
different organic mixtures 
Number % 
Extracts Total H E C Eth Total H E C Eth 
Screened 168 41 43 42 42 100 24.4 25.6 25 25 
Active 44 5 13 12 14 26 11.4 29.5 27.3 31.8 
(>50%) 
Selective 8 4 0 1 3 18.2 50 0 12.5 37.5 
EXAMPLE 2 
Identi?cation of Mycelium Crude Extracts that 
Selectively Inhibit Proliferation of K562 Cells 
[0083] The K562 active crude extracts of Example 1 were 
subjected to selectivity evaluation by monitoring growth 
inhibition of the selected extracts against other cell lines, 
including Jurkat (human T lymphoblasts), HT29 (human 
colon adenocarcinoma cells), MH3924A (rat Morris 
hepatoma), and ABAE (adult bovine aortic endothelial 
cells). 
[0084] Cells were plated in 96-well plates at 1.5><104 
cells/well. Twenty-four hours later mycelium crude extracts 
were added for an additional 24 hours followed by XTT 
determination according to manufacturer’s instructions 
(Biological Industries, Israel). Percentage of growth inhibi 
tion was calculated in relation to solvent-treated samples. 
Experiments were carried out in duplicate. The results are 
shown in Table 3. Changes in % coefficient of variance (CV) 
among duplicate samples were minimal. For example, % CV 
in growth inhibition of K562 using duplicate samples treated 
with mycelium crude extracts MH161, MH210, Meth178, 
MH17, Meth134, Meth114, MC293, MH428 were 0.4, 28, 
6.4, 1.1, 4.3, 1.9, 17.9, 4.1, respectively. This experiment 
was repeated twice with similar outcomes. 
[0085] Mycelium crude extracts that inhibited K562 by 
more than 50% and showed minimal growth inhibition (less 
than 30% inhibition) against other cell lines were designated 
as selective K562 inhibitors. Table 3 shows a list of selective 
mycelium crude extracts (with their designations and iden 
ti?cation of the mushroom strain in the ?rst two columns) 
with percentage of growth inhibition applied to a variety of 
cell lines. Growth inhibition was calculated compared with 
solvent-treated samples. 
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Effect of K562-selective mycelium crude extracts on the growth of 
K562 MH3924A ABAE HI‘—29 and .Iurkat cell lines 
% of Growth Inhibition 
Ext Mushroom Strain Solvent K5 62 MH3924A ABAE HI‘—29 .Iurkat 
MH161 Kuehneromyces 114 H 61.3 16.6 —30.1 —19.5 16.2 
mutabilis 
MH210 Pleurotus eryngii 202 H 53.8 3.4 —34.0 —27.2 8.8 
Meth178 Omphalotus 173 Eth 56.9 —14.5 —56.2 —11.3 —36.4 
olearius 
MH17 Piptopoms 241 H 68.8 15.2 28.2 —7.6 —2.9 
bemlinus 
Meth134 Ganoderma 349 Eth 59.2 —15.5 —44.7 23.1 —18.4 
adspersum 
Meth114 Panus conchatus 396 Eth 56.0 11.5 27.8 4.3 2.4 
MC293 Hypsizygus 812 C 56.7 14.4 —28.9 —7.6 7.3 
ulmarium 
MH428 Trametes zonata 540 H 69.0 —11.4 —5.1 1.9 30.1 
[0086] Table 3 shows that a total of 8 mycelium crude 
extracts exhibited selective activity against K562 cells. The 
8 positive crude extracts were distributed among the various 
extraction methods as follows: 4, 0, 1, and 3 using organic 
mixture H, E, C, and Eth, respectively. It is interesting that 
most of the selective extracts were extracted by means of the 
H and Eth organic solvents. 
EXAMPLE 3 
Effect of the Mycelium Crude Extracts on the 
Viability of K562 Cells 
[0087] It is important to note that XTT assay does not 
distinguish between cytostatic and cytotoxic effects in con 
tinuously proliferating cultures. Therefore, the effect of the 
selected mycelium crude extracts on the viability of K562 
cells was evaluated. Although cell viability can be re?ected 
by a variety of different parameters, integrity of the outer cell 
membrane is often used. The vital dye trypan blue, which is 
usually excluded from viable cells, was used to assess 
whether mycelium crude extracts function as a cytotoxic or 
a cytostatic compound against K562 cells. Cells were treated 
with 500 pig/ml of the appropriate crude extracts shown in 
Table 3 and viable cells were monitored for several days. 
[0088] K562 cells were plated in 6-well plates at 1><105 
cells/ml (day —1). Twenty-four hours later (day 0), 500 
pig/ml of mycelium crude extracts Meth 114, MH428, 
MC293, MH161, Meth178, MH210, MH17, and Meth134 
(see Table 3 for mushroom species) were added and cell 
numbers were monitored for 4 days by trypan blue exclusion 
assay as described in Materials and Methods. 
[0089] The results shown in FIG. 1 illustrate that most 
mycelium crude extracts exhibit a complete (MH210, 
Meth134, Meth114, MH326) or partial (Meth178, MH17, 
MC293) cytostatic effect. In contrast, crude extract MH161 
exhibited cytotoxic effect at the concentration used. 
EXAMPLE 4 
Involvement of the Apoptosis Pathway in 
Mediating the Growth Inhibition of K562 Cells by 
Mycelium Crude Extracts 
[0090] Apoptosis, programmed cell death, is a genetically 
controlled ablation of cells during development. Further 
more, induction of apoptosis is the principal mechanism by 
which the majority of chemotherapeutic agents exercise 
their function. Accordingly, we evaluated whether our myce 
lium crude extracts affected the apoptosis pathway in K562 
cells. Our data show that 8 mycelium crude extracts exhib 
ited selective antiproliferative effect against K562 cells as 
determined by XTT assay (Table 3) and trypan blue exclu 
sion assay (FIG. 1). 
[0091] To evaluate whether the antiproliferative effect of 
mycelium crude extracts is mediated by induction of the 
apoptosis process, we monitored changes in chromatin con 
densation as a marker of apoptosis (Allera et al., 1997). A 
recent report illustrated that formamide, a gentle denaturing 
agent, denatured DNA in apoptotic cells, but not in necrotic 
cells (Frankfurt and Krishan, 2001a, b). Apostain ELISA kit 
(Alexis Biochemicals, USA) uses the increased sensitivity 
of DNA in condensed chromatin of apoptotic cells to dena 
turation by formamide (Frankfurt and Krishan, 2001a), 
which is attributed, in part, to changes in the DNA-histone 
interactions. The increased sensitivity of cells with dena 
tured DNA is detected by a monoclonal antibody speci?c for 
single-strand DNA (Mab F7-26) in an ELISA format (Frank 
furt and Krishan, 2001b). 
[0092] K562 cells were treated with the appropriate myce 
lium crude extracts and samples were collected 48 hours 
post-treatments. Apostain ELISA assay was performed 
according to manufacturer’s instructions and as detailed in 
Materials and Methods. 
[0093] K562 cells were plated in 6 well-plates at 1><105 
cells/ml. Twenty-four hours later cells were treated with the 
mycelium crude extracts MH210, Meth178, MH17, 
Meth134, MC293, and MH428 at 250 pig/ml and 500 pig/ml 
(see Table 3). The tyrphostin AG957 at 10 pM and 20 pM 
was included as a positive control. In addition, a solvent 
treated sample was included, in which DMSO was added to 
0.6%. Forty-eight hours post treatment cells were counted 
and washed with cold PBS and subjected to Apostain ELISA 
Assay according to manufacturer’s instruction. To calculate 
relative Apostain values, empty wells were subtracted from 
absorbance values obtained from cells treated with the 
different extracts. The solvent-treated sample was assigned 
the value 1, and relative values were calculated. 
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[0094] The data shown in Table 4 illustrate the ability of 
the various mycelium crude extracts to induce an increase in 
DNA condensation. Almost all crude extracts Were able to 
induce a more than tWofold increase in DNA condensation 
above the solvent-treated sample. Mycelium crude extracts 
Meth178, MH17, Meth134, MC293, and M1428 induced 
increases in DNA condensation to values of 4.3, 3.5 3.6, 5.3, 
and 2.8, respectively, after 48-hour treatments. 
[0095] Furthermore, AG957, a knoWn p210B°I'Abl inhibi 
tor (Kaur et al., 1994), also signi?cantly induced an increase 
in DNA condensation at 10 pM. It is interesting that a higher 
dose of mycelium crude extracts caused a decrease in the 
measured signal, suggesting that at higher concentrations of 
mycelium extracts, cell death is mediated, in part, by necro 
s1s. 
TABLE 4 
Apostain values from K562 cells treated With mycelium crude extracts 
Relative Apostain Value 
Myceliurn Extract 250 ,ug/ml 500 ,ug/ml 
MH210 1.9 1.9 
Meth178 4.3 1.4 
MH17 3.5 1.6 
Meth134 3.6 3.2 
MC293 5.3 6.5 
MH428 2.8 10.9 
AG957 6.2 (10 ,uM) 3.9 (20 ,uM) 
EXAMPLE 5 
Cleavage of PARP by the Mycelium Extracts 
[0096] The execution of apoptosis requires speci?c 
molecular machinery, the central component of Which is a 
family of proteases called caspases, Which are cysteine 
proteases that cleave proteins after speci?c aspartate resi 
dues, in response to proapoptotic signals (Nicholson and 
Thornberry, 1997). During apoptosis, caspases activated in 
an amplifying proteolytic cascade, cleave one another in 
sequence (Raff, 1998). One of the most Widely studied 
caspases, caspase 3, is classi?ed as an effector caspase and 
cleaves death substrates such as the structural protein lamin 
and the nuclear protein PARP (McGoWan et al., 1996). 
[0097] K562 cells treated With the appropriate concentra 
tion of the mycelium crude extracts MH210, Meth178, 
MH17, Meth134, MC293, and MH428 for 48 hours and 
used to monitor cleavage of PARP as an indication of the 
activation of the apoptosis pathWay. Presence of cleaved 
PARP Was monitored by means of anti-PARP. Treatment 
With AG957, a knoWn Bcr-Abl inhibitor (Kaur et al., 1994), 
signi?cantly activates PARP cleavage, attesting that AG957 
promotes apoptosis in K562 cells. 
[0098] Thus, K562 cells Were plated in T25 ?asks at 1><105 
cells/ml. TWenty-four hours later, mycelium crude extracts 
MC293, MH428, tyrphostin AG957, MH210, Meth178, 
MH17, and Meth134 Were added at 500 pig/ml and 250 
pig/ml for 48 hours. Cell lysates Were resolved into 8% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) fol 
loWed by transfer to nitrocellulose ?lters. Western blotting 
Was performed (as described in Materials and Methods) in 
Which monoclonal anti-PARP antibody Was used (Santa 
CruZ Co., USA). 
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[0099] The results are shoWn in FIGS. 2A (MC293, 
MH428 and AG957) and 2B (MH210, Meth178, MH17, 
Meth134). Although most mycelium extracts shoWn failed 
to activate cleavage of PARP, extract MH428 signi?cantly 
activated PARP cleavage. 
EXAMPLE 6 
Mycelium Crude Extracts Induce Terminal 
Differentiation of K562 Cells 
[0100] Leukemic blasts expressing p210B°"Abl display 
arrested differentiation as Well as resistance to apoptosis, 
even When exposed to high doses of anti-leukemic drugs 
(Bedi et al., 1995; Ray et al., 1996). K562 is a human 
erythroleukemia cell line derived from a patient With chronic 
myelogenous leukemia (LoZZio and LoZZio, 1975). These 
cells are pluripotent in that they are able to differentiate 
along a megakaryocytic, erythroid, or, to a lesser extent, 
monocytic lineage (Leary et al., 1987). Erythroid differen 
tiation can be induced by a number of compounds, including 
hemin and butyric acid (RoWley et al., 1981). HoWever, TPA 
(or PMA) treatment induces macrophage-like morphology 
and promotes the expression of proteins associated With 
megakaryocytes (Leary et al., 1987; Burger et al., 1992). 
Erythroid differentiation is frequently monitored by induced 
expression of hemoglobin, While megakaryocyte differen 
tiation can be assessed by monitoring of the ability of treated 
K562 cells to reduce nitroblue tetraZolium (NBT) (Suther 
land et al., 1986). 
[0101] To assess erythroid differentiation, We monitored 
levels of hemoglobin production in treated cells using a 
commercially available kit (Sigma, USA). K562 cells Were 
plated at 2><105 cell/ml in 6-Well plates. TWenty-four hours 
later mycelium crude extracts at appropriate concentration 
Were added. GroWth of K562 cells in the presence of crude 
extracts Was monitored by trypan blue exclusion assays (as 
described in Materials and Methods). Numbers of viable 
cells Were monitored after 2 and 4 days post-treatment. On 
Day 5, cells Were Washed With PBS, cell pellet Was lysed, 
and levels of hemoglobin Were determined (as described in 
Materials and Methods). Hemoglobin levels Were normal 
iZed to protein concentration in each sample. Relative hemo 
globin levels Were calculated in relation to solvent-treated 
sample, Which Was designated 1.0. The experiment Was 
carried out in duplicate With minimal variations. This experi 
ment Was repeated tWice With similar outcomes. 
[0102] Levels of expressed hemoglobin assayed at day 5 
post-treatment Were normaliZed to the amount of total 
proteins present in each sample. Relative units of hemoglo 
bin Were calculated in relation to levels of hemoglobin found 
in solvent-treated samples (DMSO at 0.6%). The results 
summariZed in Table 5 shoW that butyric acid Was active in 
inducing hemoglobin expression in K562, Which is in agree 
ment With published data (Villeval et al., 1983). Further 
more, three mycelium crude extracts (Meth178, MH17 and 
MH428) Were active in inducing hemoglobin expression 
above the levels of DMSO-treated cells. Extracts MH17 and 
MH428 induced hemoglobin expression 4.2 and 2.1 times 
higher, respectively, than the solvent-treated cells. It Was 
interesting that extract Meth178 Was the most potent extract 
(about 12 times higher than DMSO-treated cells) and Was 
more active than butyric acid. 
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TABLE 5 
Induction of hemoglobin expression 
in K562 cells by mycelium crude extracts 
Concentration Relative 
Mushroom Species Strain Extract (‘ug/ml) Hemoglobin 
Kuehneromyces 114 MH161 300 0.9 
mutabilis 
Pleurotus eryngii 202 MH210 500 0.8 
Omphalotus olearius 173 Meth178 500 11.9 
Piptoporus betulinus 241 MH17 500 4.2 
Ganoderma adspersum 349 Meth134 500 0.7 
Panus conchams 396 Meth114 300 0.2 
Hypsizygus ulmarium 812 MC293 300 0.8 
T rametes zonata 540 MH428 250 2.1 
Butyric Acid 1 mM 9.4 
EXAMPLE 7 
Involvement of MAP Kinase p38 in Mediating 
Growth Inhibition of Mycelium Crude Extracts 
[0103] Previous reports indicated that proliferation and 
differentiation of K562 cells are mediated by mitogen 
activated protein kinase (MAPK) pathway (Cobb, 1999; 
Cross et al., 2000). We examined the involvement of p38 
MAPK in mediating the antiproliferative effect of the myce 
lium crude extracts. This was achieved by pretreatment of 
K562 cells with SB203580, a speci?c inhibitor of p38 kinase 
pathway, in the presence of the various mycelium crude 
extracts. 
[0104] K562 cells were plated on 96 well-plates at 1.5><104 
cells/well. Cells were pretreated with 10 pM of SB203580 
(Calbiochem, USA) 24 hours later. Mycelium crude extracts 
(see Table 3) were added at 1 mg/ml hours 3 later and 
incubated for additional 24 hours. XTT assay was carried 
out as previously described. Growth inhibition was calcu 
lated as before and relative to solvent-treated samples. The 
experiment was performed in duplicate with minimal varia 
tions. 
[0105] The data shown in Table 6 indicate that pretreat 
ment of SB203580 resulted in a moderate relief of the 
growth inhibition caused by MH161, Methl78, and MH210 
and no in?uence in MC293 and MH428 extracts. These 
results indicate that the antiproliferative function of 
Meth114, MH161, Meth178, MH17, and MH210 are par 
tially dependent on p38. Furthermore, the p38 kinase path 
way is not involved in mediating the antiproliferative effect 
of mycelium extracts MC293 and MH428. 
TABLE 6 
Involvement of MAP kinase p38 in the growth 
inhibition of K562 cells by mvcelium extracts 
Inhibition of K562 
Extract Strain — SB2035 80 (10 ,uM) 
Meth114 396 56 27.9 
MH161 114 61.3 34.3 
Meth178 173 56.9 40.2 
MH210 202 53.8 43.3 
MH17 241 68.8 46.3 
Meth134 349 59.2 47.6 
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TABLE 6-continued 
Involvement of MAP kinase p38 in the growth 
inhibition of K562 cells by mvcelium extracts 
Inhibition of K562 
Extract Strain — SB203580 (10 ,uM) 
MC293 812 56.7 70.7 
MH428 540 69 80.3 
EXAMPLE 8 
Effect of Mycelium Crude Extracts on the 
Expression of p210 Bcr-Abl in K562 Cells 
[0106] Expression of p210B°I'Abl hybrid protein is corre 
lated with carcinogenesis in CML. A number of CML 
inhibitors have been found to exert their effect by down 
regulating the expression of p2l0Bcr'Abl. We examined the 
ability of our mycelium crude extracts to affect p210B°"Abl 
expression levels. 
[0107] K562 cells were plated in T25 ?asks at 1><105 
cells/ml. Twenty-four hours later, tyrphostin AG957 (a small 
molecule inhibitor of the protein tyrosine kinase p145(abl) 
and its oncogenic derivative p210(bcr-abl)) and mushroom 
extracts MH210, Methl78, M17 (3A), tyrphostin AG957, 
Meth134, MC293, and MH428 (3B) were added at 500 
pig/ml and 250 pig/ml for 48 hours. Western blotting was 
performed (as described in Materials and Methods), in 
which monoclonal c-Abl antibody was used (Santa CruZ 
Co., USA). Filters were stripped and reprobed with loading 
control, monoclonal [3-actin antibody (Santa CruZ Co., 
USA). 
[0108] FIGS. 3A and 3B demonstrate that exposure of 
K562 cells to AG957 (10 pM and 20 pM), Methl34 (500 
pig/ml and 250 pig/ml), MH428 (500 pig/ml and 250 pig/ml), 
and MH17 (500 pig/ml and 250 pig/ml) caused a reduction in 
Bcr-Abl protein levels in K562 cells with varying potency 
(Meth 134 shows a moderate reduction). In contrast, no 
signi?cant effect on p210Bc"Abl levels was observed with 
MH210, MC293, and Meth178 mycelium extracts. Interest 
ingly, mycelium crude extract MH428 was the most potent 
of our selected crude extracts and caused a dramatic reduc 
tion in both p210B°I'Abl and normal p145 c-Abl levels. 
Moreover, the reduction of p210B°"Abl and p145 c-Abl was 
speci?c, because no effect on levels of [3-actin was detected. 
EXAMPLE 9 
Identi?cation of Mycelium Crude Extracts that 
Selectively Inhibit Proliferation of LNCaP Cells 
[0109] Mushroom crude extracts were tested for their 
ability to inhibit the growth of prostate cancer cells. We used 
the LNCaP cell line established from a metastatic lesion of 
human prostatic adenocarcinoma (HorosZewicZ et al., 1983) 
as a representative of prostate cancer cell line—it is andro 
gen-dependent for proliferation and expresses several mark 
ers of prostate cancer including the prostate-speci?c antigen 
(PSA). 
[0110] LNCaP cells were plated in 96-well plates at 1.5x 
104 cells/well. Twenty-four hours later, mycelium crude 
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extracts were added for an additional 24 hours followed by 
XTT determination according to manufacturer’s instructions 
(Biological Industries, Israel). Percentage of growth inhibi 
tion was calculated in relation to solvent-treated samples. 
Experiments were carried out in duplicate. The results are 
shown in Table 7. Changes in % coefficient of variance (CV) 
among duplicate samples were minimal. 
TABLE 7 
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[0114] The murine wild-type (WT) BaF3 pro-B-lympho 
cyte cell line depends on IL-3 for growth and viability, 
whereas the BaF3/p185, expressing the oncogenic p185Bcr 
Abl tyrosine kinase, became factor independent. The p185 
Bcr-Abl as well as p185 Bcr-Abl carrying point 
mutations E255K or T315I were cloned into PSLXBcr-Abl 
vectors and used to transform BaF3 cells. Stable BaF3/ 
Effect of LNCaP-selective mycelium crude extracts on the growth of 
MH3924A ABAE HT-29 and cell lines 
% of Growth Inhibition 
Ext Mushroom Strain Solvent LNCaP MH3924A ABAE HT-29 
Meth162 Kuehneromyces 114 Eth 60.4 26.0 25.1 18.9 
mutabilis 
Meth215 Pleurotus eryngii 202 Eth 64.2 19.5 41.7 —1.5 
Meth194 Pholiota aurivella 236 Eth 70.0 —7.0 —75.6 22.0 
Meth134 Ganoderma 349 Eth 50.0 —15.5 —44.7 23.1 
adspersum 
Meth114 Panus conchatus 396 Eth 52.4 11.5 27.8 4.3 
Meth327 Trametes zonata 540 Eth 49.9 39.8 33.6 7.4 
[0111] Mycelium crude extracts that inhibited LNCaP cell 
lines by 50% or more and also exhibited minimal growth 
inhibition against other cell lines were designated as selec 
tive LNCaP inhibitors. Table 7 shows a list of selective 
mycelium crude extracts (with their designations and iden 
ti?cation of the mushroom strain in the ?rst two columns) 
with percentage of growth inhibition applied to a variety of 
cell lines. Growth inhibition was calculated compared with 
solvent-treated samples. 
[0112] Table 7 shows that a total of 6 mycelium crude 
extracts exhibited selective activity against LNCaP cell line 
with varying potency and selectivity. It is of interesting that 
all mycelium extracts active against LNCaP were prepared 
using 70% ethanol extraction. 
EXAMPLE 10 
Resistance to imatinib Mesylate (Gleevec) in CML 
Treatment 
[0113] The tyrosine kinase p210 Bcr-Abl is the principal 
driving force in CML development, therefore modulators of 
its activity or function are expected to serve as CML 
therapeutics. Recently, imatinib mesylate (STI571, Gleevec, 
Novartis, Basel, Switzerland) was introduced as a powerful 
inhibitor of the tyrosine kinase activity of p210 Bcr-Abl and, 
thereby, as an effective therapy for CML. Although imatinib 
mesylate produces high rates of complete clinical response 
in the chronic phase, resistance is universal and clinical 
relapse develops rapidly in the advanced phase of CML 
(Gorre et al., 2001). The majority of patients resistance to 
imatinib therapy coincides with reactivation of the tyrosine 
kinase activity of the Bcr-Abl fusion oncoprotein. This can 
result from gene ampli?cation and, more importantly, from 
point mutations that disrupt the binding of imatinib to 
Bcr-Abl itself. More than 50%, and perhaps as many as 90%, 
of patients with CML relapse have Bcr-Abl point mutations 
in different amino acids scattered throughout the Abl kinase 
domain such as mutations of Thr-315 in the Abl kinase 
domain to Ile (T3151), the Tyr-253 to Phe (Y253F) or the 
E255K mutation. 
p185bcr-abl clones were selected using appropriate antibi 
otics that were growing adherent on ECM proteins (van der 
Kulp et al., 2001). BaF3 cell lines were kindly provided by 
Dr. J. Duyster (Munich, Germany). 
[0115] BaF3 cell lines carrying WT Bcr-Abl were sensi 
tive to treatment with Gleevec for both growth and phos 
phorylation of Bcr-Abl. However, BaF3 cells carrying 
mutated Bcr-Abl were resistant to Gleevec (Table 8 and 
FIG. 4). Table 8 shows that the IC5O of Gleevec for BaF3 
cell lines carrying WT Bcr-Abl was about 0.7 pM. However, 
the IC5O using the mutant Bcr-Abl T315I was higher by 
about twenty fold (14 pM). In contrast, using extract of 
T rametes zonata mushroom in 100% dichloromethane 
(DCM540), the IC5O with the two cell lines were compa 
rable, indicating that the mushroom extract is effective in 
inhibiting the growth of both the wild-type and the mutation 
carrying cell lines. FIG. 4 shows that treatment with 1 pM 
of Gleevec for 60 min causes signi?cant reduction in phos 
phorylated WT Bcr-Abl, while no reduction in the level of 
phosphorylation was seen in mutated Bcr-Abl. In contrast, 
DCM540 was equally effective in inhibiting the phospho 
rylation of WT as well as mutated Bcr-Abl., indicating that 
the extract of T rametes zonata may be useful for treatment 
of CML and of Gleevec-refractory CML. 
TABLE 8 
Growth inhibiton of BaF3/Bcr-Abl 




Compound T315I mutant 
T rametes zonata 
DCM organic 211 ,ug/ml 180 ,ug/ml 
extract (#540) 
Gleevec (STI-571) 0.7 ,uM 14 ,uM 
[0116] K562, BaF3/Bcr-Abl WT, BaF3/Bcr-Abl T3151 
and BaF3/Bcr-Abl E255K cell lines were seeded 4 mls/well 
in 6-well plates 5-6><105 cells/ml. 24 hours post-plating, 
US 2006/0045887 A1 
different concentrations of the appropriate extract or drug 
Were added. Control cells Were treated With 2% DMSO. 
Thus, cells Were treated With 1 pM Gleevec and dichlo 
romethane (DCM) extract of T zonata #540 at tWo concen 
trations: (A) at 500 pig/ml and (B) at 1000 pig/ml Were added 
after 24 hours. Cells Were treated for 60 min, then collected 
and centrifuged at 5000 rpm for 5 min. Cell pellets Were 
lysed in lysis buffer {10 mM Tris, pH 7.4; 100 mM NaCl; 
1 mM EDTA; 1 mM EGTA; 1 mM NaF; 20 mM Na4P2O7; 
2 mM Na3VO4; 1% Triton-X100; 10% glycerol; 0.1% SDS; 
0.5% deoxycholate; 1 mM PMSF; 10 pl protease inhibitor 
cocktail and phosphatase inhibitor cocktail Were added to 
every 1 ml lysate}. After that, 40 pg protein from each 
sample Were separated on 8% SDS-PAGE, and Western blot 
Was performed according to the manufacturer’s instructions 
using phospho-c-Abl (Tyr245) Antibody (Cell Signaling 
Technology Co.) and c-Abl monoclonal antibody (Santa 
CruZ Biotechnology). FIG. 5 shoWs the inhibition of Bcr 
Abl tyrosine kinase phosphorylation in BaF3 cells express 
ing the Bcr-Abl WT or the mutants Bcr-Abl T3151 and 
Bcr-Abl E255K treated With the tyrosine kinase inhibitor 
Gleevec or the #540 extract at tWo different concentrations 
A and B. FIG. 6 shoWs the inhibition of Bcr-Abl tyrosine 
kinase phosphorylation in K562 cells treated With Gleevec 
(ST1571) or the #540 extract at the same tWo different 
concentrations as in FIG. 5. 
[0117] Cell viability Was determined using trypan blue 
exclusion assay. Number of cells obtained relative to 
untreated samples at 48 hours post-treatment Were used to 
calculate percentage of inhibition and IC50 Was calculated. 
Discussion 
[0118] CML is a malignancy of pluripotent hematopoietic 
cells characteriZed by the presence of the Philadelphia (Ph) 
chromosome, Which results from reciprocal translocation 
betWeen the long arms of chromosomes 9 and 22 {(t(9;22) 
q34;q11)} resulting in the creation of the fusion gene 
p210B°I'Ab1. The bcr-abl fusion gene encodes a phosphop 
rotein (p210) that functions as a disregulated (abnormal) 
protein tyrosine kinase and predisposes the cell to become 
neoplastic. The presence of active p210B°"Abl renders CML 
cells resistant to apoptosis and delays differentiation. 
[0119] Medicinal mushrooms have been an important 
source of therapeutic substances for the treatment of various 
human diseases. Antitumor activities from mushrooms Were 
described by many reports (MiZuno, 1999; Wasser, 2002). In 
most cases, activity Was due to high-molecular-Weight 
polysaccharides With a molecular Weight of 200-400,000 D. 
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The antitumor activity of HMW polysaccharides Was attrib 
uted to the immune-modulation function or enhancement 
properties of the immune system, and not to direct in?uence 
on the tumor cells. In the present invention, We attempted to 
identify mycelium crude extracts that directly shoW antitu 
mor effects against cancer cells. Furthermore, We used 
various organic mixtures to prepare our mycelium crude 
extracts in an attempt to enrich them With loW molecular 
Weight moieties that can easily penetrate the cell Wall. 
[0120] Mycelium crude extracts prepared from our culture 
collection of Higher Basidiomycetes (these mushrooms are 
also available elseWhere) Were evaluated for their ability to 
selectively inhibit the groWth of the human CML 562 cell 
line. Using submerged conditions, We cultivated 42 species 
of Higher Basidiomycetes mushrooms and prepared 168 
mycelium crude extracts by a variety of extraction methods 
(Table 1). Initially, We evaluated the ability of our mycelium 
crude extracts to inhibit the groWth of K562 cells by more 
than 50% compared With the solvent-treated cells. Data 
shoWn in Table 2 illustrate that 44 extracts Were active in 
inhibiting K562 cells. HoWever, only 8 Were found to exhibit 
a selective effect against K562 cells (Table 3). IC5O values 
for the K562-selective extracts ranged from 250 to 500 
pig/ml. Most of the selective extracts shoWed partial or 
complete cytostatic activity and only MH161 shoWed cyto 
toxic activity against K562 cells (FIG. 1). 
[0121] The observed antiproliferative activity of the selec 
tive K562 mycelium crude extracts Was attributed to induc 
tion of apoptosis by most extracts, as determined by Apos 
tain ELISA assay. Our results indicate that groWth inhibition 
Was caused by the induction of the apoptosis pathWay and 
not as a result of necrosis. HoWever, higher concentration or 
longer exposure time can also cause death from necrosis, as 
indicated by a reduction in DNA condensation determined 
by the Apostain ELISA assay (Table 4). Data obtained by 
monitoring PARP cleavage as an indication of apoptosis 
illustrated that only our control AG957 and higher concen 
tration of MH428, and not the other mycelium crude extracts 
could cause a signi?cant cleavage of PARP. This might be 
explained by the fact that Apostain ELISA assay is a more 
sensitive measurement than the PARP cleavage assay. In 
addition, PARP cleavage assay measures a very late event in 
the apoptosis pathWay, While Apostain measures a much 
earlier event. Thus, longer exposure times might be required 
to observe signs of apoptosis by the PARP cleavage assay. 
[0122] Table 9 summariZes various characteristics of the 
extracts herein designated MH428, Meth178, MH17, 
MH210, MC293, Meth134, Meth114 and MH161. 
TABLE 9 
Characteristics of K562-selective mycelium crude extracts 
MH428 Meth178 MH17 MH210 MC293 Meth134 Meth114 MH161 
Selective Growth + + + + + + + 
Inhibition 
of K562 cells 
Down-regulation ++ +/- _ _ _ NT NT 
of Bcr-Abl 
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TABLE 9-continued 
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Characteristics of K562-selective mycelium crude extracts 
MH428 Meth178 MH17 MH210 MC293 Meth134 Meth114 MH161 
Induction + +++ ++ — — — — — 
of erythroid 
differentiation 
PARP cleavage + — — — — — NT NT 
Apostain ++++ + + + +++ ++ NT NT 
Viability Cytostatic Cytostatic Cytostatic Cytostatic Cytostatic Cytostatic Cytostatic Cytostatic 
“+”: positive activity; 
“—”: negative activity by. 
NT: not tested. 
“++” and “+++” “indicate greater potency of positive response. 
[0123] K562 cells are pluripotent cells that are able to 
differentiate along a megakaryocytic, erythroid, or, to a 
lesser extent, monocytic lineage. Erythroid differentiation 
can be induced by a number of compounds including hemin 
and butyric acid (Villeval et al., 1983). K562 selective 
mycelium crude extracts were evaluated for their ability to 
induce erythroid differentiation in K562 cells. Three 
extracts, Meth178, MH17, and MH428, showed signi?cant 
ability to induce hemoglobin production by a factor of 11.9, 
4.2, and 2.1, respectively. 
[0124] It is interesting that there was no correlation 
between the ability to induce apoptosis and to induce 
differentiation (Table 8). Mycelium crude extract Meth178 
was the most potent in inducing erythroid differentiation. 
However, it was only a moderate inducer of apoptosis as 
determined by Apostain, and it failed to activate PARP 
cleavage. Conversely, MH428 extract showed weak activity 
in inducing erythroid differentiation, while it displayed the 
most signi?cant apoptosis-inducing activity, as determined 
by both Apostain ELISA and PARP cleavage assays. Fur 
thermore, mycelium extracts MC293 and Methl34 showed 
signi?cant apoptosis activity as determined by Apostain 
ELISA assay, but failed to induce erythroid differentiation. 
Thus, the two activities are separable. At this stage, the 
molecular mechanism by which these mycelium extracts 
cause the induction of differentiation is not clear. It is worth 
noting that the hemoglobin produced in K562 is a fetal 
hemoglobin, mainly y-globin. Increased expression of the 
endogenous y-globin gene is a realistic approach to therapy 
of [3-globin disorders such as sickle cell anemia and 
[3-thalassemia (Nagel et al., 1985; Labie et al., 1985). Thus, 
our mycelium extracts, especially Meth178, has the potential 
to serve as a therapy for [3-globin disorders. 
[0125] The fusion protein p210B°"Abl plays a principal 
role in CML carcinogenesis. Consequently, down-regulation 
of p210B°"Abl is an appealing strategy for developing che 
motherapeutics for the treatment of CML. We evaluated the 
ability of our mycelium crude extracts to lower expression 
levels of p210B°"Ab1. Our data revealed that MH428 sig 
ni?cantly inhibited the expression of p210B°I'Ab1, which was 
moderately inhibited by MH17. In contrast, the other 
extracts exerted a minor effect on the expression levels of 
p210B°"Ab1. The mechanism leading to down-regulation of 
p210B°I'Abl by MH428 and MH17 is unclear. However, it is 
worth investigating whether this downregulation is caused 
by inhibition of the transcription of p210B°"Abl or by affect 
ing protein degradation. A number of compounds such as 
geldanamycin and radicicol exhibited antiproliferative effect 
againBsttAK562 cells, mediated in part by downregulation of 
p210 (Nimmanapalli et al., 2001; Shiotsu et al., 2000). 
Immune precipitation analysis showed that p210B°I'Abl 
formed multiple complexes with heat shock protein 90 
(Hsp90), some containing p23 and others Hsp70. The pres 
ence Bgfb 1geldanamycin (GA) decreased the association of 
p210 with Hsp90 and p23 and increased its association 
with the chaperones Hsp70 and p60Hop. Loss of Hsp90/p23 
association and acquisition of Hsp70/p60Hop preceded GA 
induced degradation of p210B°I'Abl (An et al., 2000). 
[0126] The MAPK pathway includes the extra cellular 
signal-regulated kinase (ERK), the c-Jun N-terminal kinase 
(J NK), and the p38 kinase modules (Cross et al., 2000). Such 
signaling pathways regulate multiple biological activities, 
including cell proliferation, differentiation, and survivals 
(Cobb, 1999). The bulk of the evidence suggests that acti 
vation of the ERK pathway increases the cell death threshold 
(Ishikawa and Kitamura, 1999). Conversely, activation of 
the JNK and p38 kinase cascades is generally associated 
with enhanced activation of the apoptosis program (Ichijo et 
al., 1997). In an attempt to elucidate the mechanism of 
action of our mycelium crude extracts, we used potent and 
selective pharmacological inhibitors to investigate the role 
of p38 in mediating the antitumor effect of our mycelium 
crude extracts. Data shown in Table 6 argue that inhibition 
of MAPK p38 partially relieves growth inhibition caused by 
some mycelium crude extracts such as Meth178, MH17, 
Meth114, MH161, and MH210 but not by MC293 and 
MH428. This argues that MAPK p38 is not the principle 
mediator of the antiproliferative function of our K562 
selective mycelium crude extracts. Similar analysis using 
additional pharmaceutical inhibitors targeting other second 
messenger pathways are required for the elucidation of the 
molecular pathways involved in mediating the anti-CML 
effect of our mycelium crude extracts. 
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1. Acomposition comprising a an extract from at least one 
higher Basidiomycetes medicinal mushroom mycelium 
separated from a culture in Which said mushroom Was 
groWn, 
said mushroom being selected from the group consisting 
of Ganoderma adspersum, Hypsizygus ulmarium, Kue 
hneromyces mutabilis, Omphalotus olearius, Panus 
conchatus, Piptoporus betulinus, Pleurotus eryngii, 
and T rametes zonata, 
said composition having selective antiproliferative activ 
ity on human chronic myelogenous leukemia K562 
cells and on human prostate cancer LNCaP cells. 
2. The composition of claim 1 Wherein said medicinal 
mushroom is Omphalotus olearius, Piptoporus betulinus, or 
T rametes zonata. 
3. The composition of claim 1 Wherein said extract is 
obtained from an extraction solvent comprising one or more 
organic solvents selected from the group consisting of 
methanol, ethanol, acetonitrile, ethyl acetate, chloroform, 
hexane, cyclohexane, isooctane and dichloromethane. 
4. The composition of claim 3 Wherein said extraction 
solvent is a non-aqueous organic solvent. 
5. The composition of claim 4 Wherein said organic 
solvent is methanol, ethanol or dichloromethane. 
6. The composition of claim 3 Wherein said extraction 
solvent is an aqueous organic solvent. 
7. The composition of claim 6 alone Wherein said extrac 
tion solvent is 70% ethanol or a mixture of ethyl acetate and 
methanol. 
8. The composition of claim 1 comprising a pharmaco 
logically acceptable carrier for treatment of a Philadelphia 
Chromosome-Positive Leukemia consisting of chronic 
myelogenous leukemia and Ph+ acute lymphoblastic leuke 
mia. 
9. The composition of claim 8 comprising a mycelium 
extract of Piptoporus betulinus or T rametes zonata. 
10. The composition of claim 1 comprising a pharmaco 
logically acceptable carrier for treatment of prostate cancer. 
11. The composition of claim 10 comprising a mycelium 
extract of T rametes zonata. 
12. The composition of claim 1 comprising a pharmaco 
logically acceptable carrier for treatment of a [3-globin 
disorder consisting of sickle cell anemia and [3-thalassemia. 
13. The composition of claim 12 comprising a mycelium 
extract of Omphalotus olearius, Piptoporus betulinus, or 
T rametes zonata. 
14. A food or beverage comprising the composition of 
claim 1. 
15. A method of treating chronic myelogenous leukemia 
comprising administering to a patient in need a therapeuti 
cally effective amount of a composition of claim 1. 

